Joanna Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joanna Li has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Antoine Bouchard
Institut de Recherches Cliniques de Montréal , Montreal, Quebec
3 shared publications - Jinsam Chang
Institut de Recherches Cliniques de Montréal , Montreal, Quebec
3 shared publications - Vincent Panneton
Institut de Recherches Cliniques de Montréal , Montreal, Quebec
3 shared publications - Woong-Kyung Suh
Institut de Recherches Cliniques de Montréal (IRCM)
3 shared publications Behnaz Behmand
Medical Physics Unit, Department of Oncology, Faculty of Medicine McGill University Montréal Québec Canada
2 shared publications- Ciriaco A. Piccirillo
Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada
1 shared publication
Latest Publications
- Open Access
- 15 July 2025
- Published by Wiley in Medical Physics
- Vol. 52 (7) , e17979
Microdosimetry calculations in situ for clinically relevant photon sources and their correlation with the early DNA damage response
Background: Radiobiological data suggests variations in relative biological effectiveness (RBE) between clinically used photon‐based sources. A microdosimetric formalism using Monte Carlo (MC) methods can mechanistically describe the photon RBE. Experimentally derived RBE based on DNA double‐strand breaks () has been shown to scale with the microdosimetry quantity dose‐mean lineal energy (). Purpose: To calculate microdosimetric spectra for clinically relevant photon sources, spanning from soft x‐rays produced by a 50 kVp x‐ray source through various brachytherapy sources up to a 6 MV medical linac. Furthermore, we investigated the correlation between and of different photon sources. Methods: Photon sources simulated include low‐energy x‐rays (50 kVp), orthovoltage x‐rays (225 kVp), high‐dose‐rate brachytherapy sources ( 75 Se, 192 Ir and 60 Co), and a 6 MV medical linac. Secondary electron spectra at the cellular level were calculated for in vitro cell irradiation setups using Geant4 MC‐based packages, RapidBrachyMCTPS and RapidExternalBeam. The obtained spectra were used in MicroDose, a microdosimetry simulation software, to obtain microdosimetric quantities, including single‐event lineal energy () and specific energy () spectra, and dose‐mean and frequency‐mean quantities (, , , ). Uniform spherical targets (1–14 radius) and realistic HeLa and PC3 cell nucleus models were simulated using cell size data obtained from literature and nuclei size data from confocal microscopy imaging. Radiobiological experiments using foci quantified DNA double‐strand breaks for HeLa and PC3 cells after irradiations with 50 and 225 kVp, 192 Ir, and 6 MV linac, and was determined using 225 kVp as the reference. Results: The calculated () is within the 3.5–1.2 keV/ range (1.8–0.2 keV/) for 1 simulated target size between the lowest energy 50 kVp x‐ray source and the highest energy 6 MV linac source, respectively. For the HeLa and PC3 cell nuclei models based on microscopy data, () spans from 1.6 to 0.6 keV/ (0.7 to 0.2 keV/). When compared between different target sizes, () ranges from 3.5 to 1.0 (1.8–0.4) keV/ between 1 and 10 radius targets for the 50 kVp x‐ray source. A smaller change is observed for 6 MV linac, ranging from 1.2 to 0.5 keV/ and 0.23 to 0.22 keV/ for and , respectively. For the simulated 75 Se source currently under investigation, the calculated values are 11%–24% higher relative to those of 192 Ir in the range of target sizes between 1 and 14 in radius. for HeLa cells was 1.40.7 for 50 kVp x‐rays, 0.50.2 for 192 Ir, and 0.70.4 for 6 MV linac irradiations. For PC3 cells, was 1.30.6, 0.80.4 and 0.50.3 for 50 kVp, 192 Ir and 6 MV linac, respectively. Measured values are consistent with ratios of the corresponding photon sources for HeLa and PC3 nucleus models. Conclusions: Microdosimetric spectra strongly depend on the simulated energy of photon sources and target size, with and decreasing by a factor of 2–3 between diagnostic 50 kVp and 6 MV therapeutic x‐rays for target sizes from 1–14 in radius. The early damage indicates this stochastic change in energy density between various photon sources as the yields of foci per nucleus scale with of the source.
- 15 July 2025
- Published by Wiley in Medical Physics
- Vol. 52 (7) , e17979
Open AccessMicrodosimetry calculations in situ for clinically relevant photon sources and their correlation with the early DNA damage response
Background: Radiobiological data suggests variations in relative biological effectiveness (RBE) between clinically used photon‐based sources. A microdosimetric formalism using Monte Carlo (MC) methods can mechanistically describe the photon RBE. Experimentally derived RBE based on DNA double‐strand breaks () has been shown to scale with the microdosimetry quantity dose‐mean lineal energy (). Purpose: To calculate microdosimetric spectra for clinically relevant photon sources, spanning from soft x‐rays produced by a 50 kVp x‐ray source through various brachytherapy sources up to a 6 MV medical linac. Furthermore, we investigated the correlation between and of different photon sources. Methods: Photon sources simulated include low‐energy x‐rays (50 kVp), orthovoltage x‐rays (225 kVp), high‐dose‐rate brachytherapy sources ( 75 Se, 192 Ir and 60 Co), and a 6 MV medical linac. Secondary electron spectra at the cellular level were calculated for in vitro cell irradiation setups using Geant4 MC‐based packages, RapidBrachyMCTPS and RapidExternalBeam. The obtained spectra were used in MicroDose, a microdosimetry simulation software, to obtain microdosimetric quantities, including single‐event lineal energy () and specific energy () spectra, and dose‐mean and frequency‐mean quantities (, , , ). Uniform spherical targets (1–14 radius) and realistic HeLa and PC3 cell nucleus models were simulated using cell size data obtained from literature and nuclei size data from confocal microscopy imaging. Radiobiological experiments using foci quantified DNA double‐strand breaks for HeLa and PC3 cells after irradiations with 50 and 225 kVp, 192 Ir, and 6 MV linac, and was determined using 225 kVp as the reference. Results: The calculated () is within the 3.5–1.2 keV/ range (1.8–0.2 keV/) for 1 simulated target size between the lowest energy 50 kVp x‐ray source and the highest energy 6 MV linac source, respectively. For the HeLa and PC3 cell nuclei models based on microscopy data, () spans from 1.6 to 0.6 keV/ (0.7 to 0.2 keV/). When compared between different target sizes, () ranges from 3.5 to 1.0 (1.8–0.4) keV/ between 1 and 10 radius targets for the 50 kVp x‐ray source. A smaller change is observed for 6 MV linac, ranging from 1.2 to 0.5 keV/ and 0.23 to 0.22 keV/ for and , respectively. For the simulated 75 Se source currently under investigation, the calculated values are 11%–24% higher relative to those of 192 Ir in the range of target sizes between 1 and 14 in radius. for HeLa cells was 1.40.7 for 50 kVp x‐rays, 0.50.2 for 192 Ir, and 0.70.4 for 6 MV linac irradiations. For PC3 cells, was 1.30.6, 0.80.4 and 0.50.3 for 50 kVp, 192 Ir and 6 MV linac, respectively. Measured values are consistent with ratios of the corresponding photon sources for HeLa and PC3 nucleus models. Conclusions: Microdosimetric spectra strongly depend on the simulated energy of photon sources and target size, with and decreasing by a factor of 2–3 between diagnostic 50 kVp and 6 MV therapeutic x‐rays for target sizes from 1–14 in radius. The early damage indicates this stochastic change in energy density between various photon sources as the yields of foci per nucleus scale with of the source.
- Open Access
- 3 July 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (13) , 135011
Monte Carlo-based dosimetry and optimization of a custom alpha cell irradiation setup
Objective. When combined with targeting agents, α-particle-emitting radionuclides show promise in treating hypoxic tumors and micrometastases. These radionuclides exhibit a high relative biological effectiveness (RBE), attributed to their high linear energy transfer, and induce complex DNA damage within targeted cells. However, most clinical experience and radiobiological data are derived from photon irradiation. To optimize α-particle-based treatments, further research is needed to refine their RBE estimates. This study aimed to characterize and optimize a custom in-vitro cell irradiation setup for α-particle RBE studies using 241Am through Monte Carlo simulations. Approach. A Geant4-based Monte Carlo simulation model was used to simulate a custom cell well setup. An 241Am (48 kBq) source was positioned beneath the well with an adjustable source-to-surface distance (SSD). The spectra of decay products was calculated with 6.5 × 10 9 simulated 241Am decay events. Simulations were conducted for SSD values of 2 mm, 5 mm, and 7 mm under three scenarios: (A) total dose rate from all decay products, (B) excluding γ-emissions, and (C) excluding secondary particles. Results were compared to published spectra and a published dose rate (0.1 Gy min−1) as validation. Main results. The validation dose rate was 0.1136 Gy min−1. Photons of 13.9–59.5 keV and α-particles of 5.39–5.48 MeV were observed. The dose inhomogeneity across the cells was around 30%, 10%, and 5% in the 2, 5, and 7 mm SSD setups, respectively. The corresponding total dose rates in cells for the three SSDs were 0.583, 0.146, and 0.0830 Gy min−1. The dose rate contributions were 90% from α-particles, less than 0.07% from γ-emissions, and 9%–10% from secondary particles. Significance. To accurately assess radiobiological effects, it is important to consider the full decay spectrum of radionuclides and their secondary particles in dosimetry calculations. These findings will aid in refining experimental setups for future in-vitro studies, contributing to more reliable RBE calculations.
- 3 July 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (13) , 135011
Open AccessMonte Carlo-based dosimetry and optimization of a custom alpha cell irradiation setup
Objective. When combined with targeting agents, α-particle-emitting radionuclides show promise in treating hypoxic tumors and micrometastases. These radionuclides exhibit a high relative biological effectiveness (RBE), attributed to their high linear energy transfer, and induce complex DNA damage within targeted cells. However, most clinical experience and radiobiological data are derived from photon irradiation. To optimize α-particle-based treatments, further research is needed to refine their RBE estimates. This study aimed to characterize and optimize a custom in-vitro cell irradiation setup for α-particle RBE studies using 241Am through Monte Carlo simulations. Approach. A Geant4-based Monte Carlo simulation model was used to simulate a custom cell well setup. An 241Am (48 kBq) source was positioned beneath the well with an adjustable source-to-surface distance (SSD). The spectra of decay products was calculated with 6.5 × 10 9 simulated 241Am decay events. Simulations were conducted for SSD values of 2 mm, 5 mm, and 7 mm under three scenarios: (A) total dose rate from all decay products, (B) excluding γ-emissions, and (C) excluding secondary particles. Results were compared to published spectra and a published dose rate (0.1 Gy min−1) as validation. Main results. The validation dose rate was 0.1136 Gy min−1. Photons of 13.9–59.5 keV and α-particles of 5.39–5.48 MeV were observed. The dose inhomogeneity across the cells was around 30%, 10%, and 5% in the 2, 5, and 7 mm SSD setups, respectively. The corresponding total dose rates in cells for the three SSDs were 0.583, 0.146, and 0.0830 Gy min−1. The dose rate contributions were 90% from α-particles, less than 0.07% from γ-emissions, and 9%–10% from secondary particles. Significance. To accurately assess radiobiological effects, it is important to consider the full decay spectrum of radionuclides and their secondary particles in dosimetry calculations. These findings will aid in refining experimental setups for future in-vitro studies, contributing to more reliable RBE calculations.
- Open Access
- 4 October 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 69 (20) , 205008
Relative biological effectiveness of clinically relevant photon energies for the survival of human colorectal, cervical, and prostate cancer cell lines
Objective. Relative biological effectiveness (RBE) differs between radiation qualities. However, an RBE of 1.0 has been established for photons regardless of the wide range of photon energies used clinically, the lack of reproducibility in radiobiological studies, and outdated reference energies used in the experimental literature. Moreover, due to intrinsic radiosensitivity, different cancer types have different responses to radiation. This study aimed to characterize the RBE of clinically relevant high and low photon energies in vitro for three human cancer cell lines: HCT116 (colon), HeLa (cervix), and PC3 (prostate). Approach. Experiments were conducted following dosimetry protocols provided by the American Association of Physicists in Medicine. Cells were irradiated with 6 MV x-rays, an 192Ir brachytherapy source, 225 kVp and 50 kVp x-rays. Cell survival post-irradiation was assessed using the clonogenic assay. Survival fractions were fitted using the linear quadratic model, and survival curves were generated for RBE calculations. Main results. Cell killing was more efficient with decreasing photon energy. Using 225 kVp x-rays as the reference, the HCT116 RBESF0.1 for 6 MV x-rays, 192Ir, and 50 kVp x-rays were 0.89 ± 0.03, 0.95 ± 0.03, and 1.24 ± 0.04; the HeLa RBESF0.1 were 0.95 ± 0.04, 0.97 ± 0.05, and 1.09 ± 0.03, and the PC3 RBESF0.1 were 0.84 ± 0.01, 0.84 ± 0.01, and 1.13 ± 0.02, respectively. HeLa and PC3 cells had varying radiosensitivity when irradiated with 225 and 50 kVp x-rays. Significance. This difference supports the notion that RBE may not be 1.0 for all photons through experimental investigations that employed precise dosimetry. It highlights that different cancer types may not have identical responses to the same irradiation quality. Additionally, the RBE of clinically relevant photons was updated to the reference energy of 225 kVp x-rays.
- 4 October 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 69 (20) , 205008
Open AccessRelative biological effectiveness of clinically relevant photon energies for the survival of human colorectal, cervical, and prostate cancer cell lines
Objective. Relative biological effectiveness (RBE) differs between radiation qualities. However, an RBE of 1.0 has been established for photons regardless of the wide range of photon energies used clinically, the lack of reproducibility in radiobiological studies, and outdated reference energies used in the experimental literature. Moreover, due to intrinsic radiosensitivity, different cancer types have different responses to radiation. This study aimed to characterize the RBE of clinically relevant high and low photon energies in vitro for three human cancer cell lines: HCT116 (colon), HeLa (cervix), and PC3 (prostate). Approach. Experiments were conducted following dosimetry protocols provided by the American Association of Physicists in Medicine. Cells were irradiated with 6 MV x-rays, an 192Ir brachytherapy source, 225 kVp and 50 kVp x-rays. Cell survival post-irradiation was assessed using the clonogenic assay. Survival fractions were fitted using the linear quadratic model, and survival curves were generated for RBE calculations. Main results. Cell killing was more efficient with decreasing photon energy. Using 225 kVp x-rays as the reference, the HCT116 RBESF0.1 for 6 MV x-rays, 192Ir, and 50 kVp x-rays were 0.89 ± 0.03, 0.95 ± 0.03, and 1.24 ± 0.04; the HeLa RBESF0.1 were 0.95 ± 0.04, 0.97 ± 0.05, and 1.09 ± 0.03, and the PC3 RBESF0.1 were 0.84 ± 0.01, 0.84 ± 0.01, and 1.13 ± 0.02, respectively. HeLa and PC3 cells had varying radiosensitivity when irradiated with 225 and 50 kVp x-rays. Significance. This difference supports the notion that RBE may not be 1.0 for all photons through experimental investigations that employed precise dosimetry. It highlights that different cancer types may not have identical responses to the same irradiation quality. Additionally, the RBE of clinically relevant photons was updated to the reference energy of 225 kVp x-rays.
- 12 July 2024
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 213 (5) , 753-762
ICOS-expressing Regulatory T Cells Influence the Composition of Antitumor CTL Populations
The role of ICOS in antitumor T cell responses and overall tumor progression has been controversial. In this study, we compared tumor progression in mice lacking ICOS selectively in regulatory T (Treg) cells or in all T cells. Using an experimental melanoma lung metastasis model, we found that Treg cell–specific ICOS knockout reduces the overall tumor burden compared with Cre control mice, with increased CD4+-to-Treg cell and CD8+-to-Treg cell ratios in the tumor. In contrast, there was no difference in the tumor burden in mice lacking ICOS in all of the T cell compartments. This suggests a dual role of ICOS costimulation in promoting protumor and antitumor T cell responses. Consistent with reduced tumor burden, we found that Treg cell–specific deletion of ICOS leads to an increase of CD8+ CTLs that express high levels of granzyme B and perforin. Moreover, single-cell transcriptome analysis revealed an increase of Ly108+Eomeshi CD8+ T cells at the cost of the Ly108+T-bethi subset in Treg cell–specific knockout mice. These results suggest that ICOS-expressing Treg cells suppress the CTL maturation process at the level of Eomes upregulation, a critical step known to drive perforin expression and cytotoxicity. Collectively, our data imply that cancer immunotherapies using ICOS agonist Abs may work better in Treg cell–low tumors or when they are combined with regimens that deplete tumor-infiltrating Treg cells.
- 12 July 2024
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 213 (5) , 753-762
ICOS-expressing Regulatory T Cells Influence the Composition of Antitumor CTL Populations
The role of ICOS in antitumor T cell responses and overall tumor progression has been controversial. In this study, we compared tumor progression in mice lacking ICOS selectively in regulatory T (Treg) cells or in all T cells. Using an experimental melanoma lung metastasis model, we found that Treg cell–specific ICOS knockout reduces the overall tumor burden compared with Cre control mice, with increased CD4+-to-Treg cell and CD8+-to-Treg cell ratios in the tumor. In contrast, there was no difference in the tumor burden in mice lacking ICOS in all of the T cell compartments. This suggests a dual role of ICOS costimulation in promoting protumor and antitumor T cell responses. Consistent with reduced tumor burden, we found that Treg cell–specific deletion of ICOS leads to an increase of CD8+ CTLs that express high levels of granzyme B and perforin. Moreover, single-cell transcriptome analysis revealed an increase of Ly108+Eomeshi CD8+ T cells at the cost of the Ly108+T-bethi subset in Treg cell–specific knockout mice. These results suggest that ICOS-expressing Treg cells suppress the CTL maturation process at the level of Eomes upregulation, a critical step known to drive perforin expression and cytotoxicity. Collectively, our data imply that cancer immunotherapies using ICOS agonist Abs may work better in Treg cell–low tumors or when they are combined with regimens that deplete tumor-infiltrating Treg cells.
- 15 July 2022
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 209 (2) , 301-309
ICOS-Deficient Regulatory T Cells Can Prevent Spontaneous Autoimmunity but Are Impaired in Controlling Acute Inflammation
ICOS is induced in activated T cells and its main role is to boost differentiation and function of effector T cells. ICOS is also constitutively expressed in a subpopulation of Foxp3+ regulatory T cells under steady-state condition. Studies using ICOS germline knockout mice or ICOS-blocking reagents suggested that ICOS has supportive roles in regulatory T (Treg) cell homeostasis, migration, and function. To avoid any compounding effects that may arise from ICOS-deficient non–Treg cells, we generated a conditional knockout system in which ICOS expression is selectively abrogated in Foxp3-expressing cells (ICOS FC mice). Compared to Foxp3-Cre control mice, ICOS FC mice showed a minor numerical deficit of steady-state Treg cells but did not show any signs of spontaneous autoimmunity, indicating that tissue-protective Treg populations do not heavily rely on ICOS costimulation. However, ICOS FC mice showed more severe inflammation in oxazolone-induced contact hypersensitivity, a model of atopic dermatitis. This correlated with elevated numbers of inflammatory T cells expressing IFN-γ and/or TNF-α in ICOS FC mice compared with the control group. In contrast, elimination of ICOS in all T cell compartments negated the differences, confirming that ICOS has a dual positive role in effector and Treg cells. Single-cell transcriptome analysis suggested that ICOS-deficient Treg cells fail to mature into T-bet+CXCR3+ “Th1-Treg” cells in the draining lymph node. Our results suggest that regimens that preferentially stimulate ICOS pathways in Treg cells might be beneficial for the treatment of Th1-driven inflammation. Key Points ICOS-deficient Treg cells can suppress spontaneous autoimmunity. ICOS-deficient Treg cells show impaired differentiation of Th1-Treg cells.
- 15 July 2022
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 209 (2) , 301-309
ICOS-Deficient Regulatory T Cells Can Prevent Spontaneous Autoimmunity but Are Impaired in Controlling Acute Inflammation
ICOS is induced in activated T cells and its main role is to boost differentiation and function of effector T cells. ICOS is also constitutively expressed in a subpopulation of Foxp3+ regulatory T cells under steady-state condition. Studies using ICOS germline knockout mice or ICOS-blocking reagents suggested that ICOS has supportive roles in regulatory T (Treg) cell homeostasis, migration, and function. To avoid any compounding effects that may arise from ICOS-deficient non–Treg cells, we generated a conditional knockout system in which ICOS expression is selectively abrogated in Foxp3-expressing cells (ICOS FC mice). Compared to Foxp3-Cre control mice, ICOS FC mice showed a minor numerical deficit of steady-state Treg cells but did not show any signs of spontaneous autoimmunity, indicating that tissue-protective Treg populations do not heavily rely on ICOS costimulation. However, ICOS FC mice showed more severe inflammation in oxazolone-induced contact hypersensitivity, a model of atopic dermatitis. This correlated with elevated numbers of inflammatory T cells expressing IFN-γ and/or TNF-α in ICOS FC mice compared with the control group. In contrast, elimination of ICOS in all T cell compartments negated the differences, confirming that ICOS has a dual positive role in effector and Treg cells. Single-cell transcriptome analysis suggested that ICOS-deficient Treg cells fail to mature into T-bet+CXCR3+ “Th1-Treg” cells in the draining lymph node. Our results suggest that regimens that preferentially stimulate ICOS pathways in Treg cells might be beneficial for the treatment of Th1-driven inflammation. Key Points ICOS-deficient Treg cells can suppress spontaneous autoimmunity. ICOS-deficient Treg cells show impaired differentiation of Th1-Treg cells.
- Open Access
- 1 January 2020
- Published by XMLink in Immune Network
- Vol. 20 (5) , e36
Hippo Signal Transduction Mechanisms in T Cell Immunity
Bouchard A, et al. Immune Netw. 2020 Oct;20(5):e36. https://doi.org/10.4110/in.2020.20.e36
- 1 January 2020
- Published by XMLink in Immune Network
- Vol. 20 (5) , e36
Open AccessHippo Signal Transduction Mechanisms in T Cell Immunity
Bouchard A, et al. Immune Netw. 2020 Oct;20(5):e36. https://doi.org/10.4110/in.2020.20.e36